In this study, we produced a new anti-TLR2 antibody and investigated its blocking effects on agonists-stimulated mouse macrophage cell line RAW264.7 in vitro and on OVA-specific allergic mice from PGN-induced lethal anaphylaxis, which provides a novel strategy to prevent TLR2 agonist-mediated inflammation and promotion of allergic immune responses. Here, TLR2 is linked to anaphylaxis.